TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients (\<18 years) and adult patients (up to 21 years still in our clinic)~* requiring long-term (\>3 months) home parenteral nutrition due to intestinal failure/short bowel syndrome~* has had at least one central line-associated blood stream infection~Exclusion Criteria:~* known cardiac arrhythmias~* hypersensitivity to citrate~* pregnancy~* receiving continuous parenteral nutrition (infusing over 24 hours)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Sodium citrate 4% (Type: EXPERIMENTAL): All enrolled participants will received the daily sodium citrate 4% locking solution for CLABSI prophylaxis intervention and be observed prospectively for adverse events

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of RING on Gastroesophageal Reflux (GERD) After RYGBP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indications for bariatric surgery (BMI over 40Kg/m2 or over 35Kg/m2 associated to a life-treating morbid conditions.~* Acceptance to be submitted to a 24h pH-monitoring and esophageal manometry~* No contra-indication for gastric bypass~* Absence of previous gastric surgery~* Option for open gastric bypass~Exclusion Criteria:~* Inferior and superior total teeth prosthesis~* Poor surgical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 58 Years
- Healthy Volunteers: f

Study Arms:
- no ring (Type: SHAM_COMPARATOR): Patients at this group will have RING REMOVED AT THE END OF SURGERY.
- RYGBP-Ring (Type: ACTIVE_COMPARATOR): Open Roux-en-Y gastric bypass with a silastic ring which is performed with linear cut stapler 100 mm and a biliopancreatic limb of 60 cm long and a alimentary limb of 100 cm long. All patients will have a 6.5 cm silastic ring located at the middle of the pouch above of the gastroenteroanastomosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be \>= 18 years of age~* Patients must be newly diagnosed with primary invasive ductal breast adenocarcinoma.~* Tumor classified as clinically stage T2, T3 or T4 with any N (NX, N1, N2, or N3).~* Tumor does not express the following biomarkers: estrogen receptor, progesterone receptor, Her2/neu~* Adequate organ function defined as:~  * Serum Creatinine \<= 1.5 x upper limit of institutional normal.~ * ALT, AST, ALK Phos \<= 1.5 x upper limit of institutional normal.~ * Bilirubin \<= 1.5 x upper limit of institutional normal.~ * Normal left ventricular function (LVEF \> 50%) by MUGA or ECHO.~Exclusion Criteria:~* No evidence of distant metastasis present by CT, Bone scan, or physical exam. If the bone scan or CT scans demonstrate indeterminate lesions, the nature of these lesions should be further clarified by additional testing such as PET or MRI.~* No prior malignancies with the exception of curatively treated basal or squamous carcinoma of the skin or history of previous malignancies, treated with at least greater than 5 years disease free survival.~* Women of child bearing potential may not be currently pregnant or breastfeeding at time of registration and must agree to use adequate contraception.~* Karnofsky Performance Status of \<= 70.~* Patients with known history neural deficiencies (e.g. peripheral neuropathy).~* Patients with a known hearing impairment (hearing loss or severe tinnitus).~* Male patients

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cisplatin + Radiation + Recommended Surgery (Type: EXPERIMENTAL): Cisplatin 75 mg/m\^2 IV Day 1 Week 1, Day 1 Week 2, Day 1 Week 7, Day 1 Week 10~Radiation = Total dose to breast or chest wall will be 50-60 Gy in 1.8-2.0 Gy daily fractions. Internal mammary nodes, supraclavicular fossa nodes and axillary nodal basins will receive 45-50 Gy over 5-6 weeks.~Surgery (recommended) mastectomy with/without axillary lymph node dissection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine for the Treatment of Delirium After Heart Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 65 years~* Clinical need for treatment of psychomotor confusion unresponsive to standard analgesic medication (RASS +2 to +3)~* Heart surgery and extracorporeal circulation (ECC) within 7 days~* Written informed consent obtained before surgery~* Mentally competent at the time of written informed consent~Exclusion Criteria:~* Ongoing neuroleptic, propofol and α2 agonist medication~* Intubated patient~* Uncompensated acute circulatory failure at time of randomisation (severe hypotension with mean arterial pressure \< 55 mmHg despite volume, vasopressors and IABP)~* Severe bradycardia without pacemaker backup (heart rate \< 50 beats/min)~* AV-conduction block II-III (without pacemaker backup)~* Severe hepatic impairment (Serum bilirubin \> 101 µmol/l)~* Lithium therapy

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: EXPERIMENTAL): None
- Haloperidol (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eastern Cooperative Oncology Group (ECOG) status of 0-3~* Active leukemia and Burkitt leukemia/lymphoma treated in-house that puts them at risk for tumor lysis syndrome (TLS)~* Serum uric acid level \>= 7.5mg/dL and high risk for TLS as defined by:~  * A diagnosis of acute myeloid leukemia (AML), or~ * A diagnosis of blast-phase chronic myeloid leukemia (CML), or~ * A diagnosis of high-grade myelodysplastic syndrome (MDS) with \>= 10% blast bone marrow blast involvement, or~ * Acute lymphoblastic leukemia (ALL), or~ * Burkitt leukemia/lymphoma~* Patient or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure~Exclusion Criteria:~* History of asthma~* History of severe or life threatening atopic allergy~* Hypersensitivity to uricases~* Known prior sensitivity to allopurinol~* Known glucose-6-phosphate dehydrogenase (G6PD) deficiency~* Recent prior history of uricolytic therapy defined as therapy within the last 7 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (1.5mg rasburicase) (Type: EXPERIMENTAL): Patients receive 1.5mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.
- Arm II (3 mg rasburicase) (Type: EXPERIMENTAL): Patients receive 3 mg of rasburicase IV over 30 minutes on day 1 and allopurinol PO QD on days 1-6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects are to have identifiable painful myofascial trigger points in the masseter, temporalis, and medial and lateral pterygoid muscles.~* Subjects will be examined by the principle investigators to determine if the individual is a suitable candidate for the study, based on active trigger points and willingness to participate in the study~Exclusion Criteria:~* Pregnant woman will be excluded from participation as potential risk is noted in product label indications. Individuals over the age of 65 will be excluded per product label indications that reflect lack of data in individuals over age 65.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Lidocaine (Type: ACTIVE_COMPARATOR): lidocaine injection group
- Botulinum (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed Binet Stage B or C B-CLL as defined by the National Cancer Institute (NCI) sponsored working group who have received up to 2 previous lines of treatment, one of which was fludarabine based. The two previous treatments could have included combination therapies.~* Patients must be ≥18 years of age, have a life expectancy of \>6 months, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. - Female patients must not be pregnant (as confirmed by negative pregnancy test for women of childbearing potential) and female and male patients must be willing to use effective contraception for the entire duration of treatment and 2 months thereafter.~Exclusion Criteria:~* Patients who have received more than 2 previous lines of treatment will be excluded from this study.~* Additional groups of patients who may not participate in the study include: patients who are pregnant and/or nursing; patients on corticosteroid treatment; patients with active infection (bacterial, viral or fungal) or severe infection (WHO 4th degree) within the last 3 months; patients with total bilirubin \> 2 × ULN; patients with calculated creatinine clearance \<70 mL/min; patients with seropositivity for human immunodeficiency virus, hepatitis B virus, or hepatitis C virus; patients with any coexisting medical or psychological condition that would preclude participation in the required study procedures; patients who have participated in another clinical study \<6 weeks prior to this study; or patients with a known hypersensitivity to the study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria Have a minimum total score of 16 on the JCY-BOCS, Weight is within the standard weight ± 2S.D. based on the standard weight for each age in the School Health Statistical Survey Exclusion Criteria Have the following predominant psychiatric diagnosis -Schizophrenia Have previously been treated with fluvoxamine maleate

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- F (Type: EXPERIMENTAL): None
- P (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid To Reduce Bleeding in Patients Treated With New Oral Anticoagulants Undergoing Dental Extraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients scheduled for dental extraction and treated with edoxaban, apixaban, rivaroxaban or dabigatran~* Not having taken the direct oral anticoagulant on the day of the extraction~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~Exclusion Criteria:~* Subjects with any condition that as judged by the Investigator would place the subject at increased risk of harm if he/she participated in the study.~* Pregnancy or lactation~* Known allergic reaction to tranexamic acid

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): 10mL water as mouthwash with white cherry flavor in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).
- Tranexamic Acid Group (Type: EXPERIMENTAL): 10mL tranexamic acid mouthwash 10% in oral syringes. Once before tooth extraction and 3 times daily during 3 days post-extraction (starting day after extraction).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Chitodex Gel Vs NexFoam on Post-operative Outcomes in the Treatment of Chronic Rhinosinusitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Those who have had symptoms of chronic rhinosinusitis (nasal discharge, postnasal drip, nasal obstruction, facial pain and pressure, lack of sense of smell) that has been previously persistent for greater than 3 months AND~2. ≥ 18 years to ≤ 90 years AND~3. English speaking AND~4. Able to give written informed consent AND~5. Local residents who will be returning to this center for postoperative follow-up care AND~6. Indicated to undergo endoscopic sinus surgery and willing to return at 2-4, 6-8 \& 12 (± 2) weeks post-op.~Exclusion Criteria:~1. allergy to shellfish~2. pregnant or breastfeeding~3. Hepatitis or blood disorders~4. any drug allergy~5. allergy to potato starch (due to Nexfoam)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Chitogel (Type: None): Chitodex gel plus Kenalog inserted into the middle meatus
- Nexfoam (Type: None): NexFoam plus Kenalog inserted into the middle meatus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of ABP-671 in Participants With Gout

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have completed the double-blind Treatment Period in Study ABP-671-301 (Part 1 or Part 2) and are actively receiving and tolerating the study drug up to the Week 28 visit in Study ABP-671-301~Exclusion Criteria:~* Has a new medical or psychological condition that, in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the participant, interfere with the participant's ability to comply with the protocol requirements to complete the Extension Study, or potentially compromise the results or interpretation of the Extension Study.~* Is planning to become pregnant or breastfeed during the study or within ≤30 days after the last dose of the study drug.~* Is intolerant or unwilling to take colchicine or naproxen.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ABP-671 (Type: EXPERIMENTAL): None
- Allopurinol (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Near Infrared Light for the Treatment of Painful Peripheral Neuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults ages 18-85; able to give informed consent~* Documented painful, distal peripheral neuropathy of idiopathic cause, or related to impaired glucose tolerance or diabetes mellitus.~* Neuropathy documented by one of the following studies: nerve conduction studies and needle electromyography (EMG); quantitative sensory testing of the foot with Computer Aided Sensory Evaluator (CASE IV); quantitative sudomotor axon reflex test (Quantitative Sweat MeasurementSystem \[Q-Sweat\]); neurology specialty examination; and neuropathy impairment score (NIS) of less than 25.~* Stable pharmacotherapy for neuropathic pain for at least two weeks.~* Optimal pharmacotherapy has been achieved.~* Subjects cannot be on Cyclooxygenase-2 (COX 2) inhibitors~* Pain Visual Analog Scale (VAS) of greater than or equal to 4/10~* Subject has provided written informed consent~* Not currently using transcutaneous electrical nerve stimulation (TENS)~* Not currently receiving acupuncture~Exclusion Criteria:~* Pregnant or likely to become pregnant~* Current diagnosis of cancer~* Neuropathy impairment score (NIS) of greater than 25.~* Diagnosis of severe neuropathy of known etiology for which specific treatment is available (i.e., acute and chronic inflammatory polyradiculoneuropathies, vasculitis, B 12 deficiency).~* Unstable diabetes mellitus defined as a hemoglobin A1c (HbA1c) greater than 9%, and/or 10% of fasting blood sugars greater than 300 mg/dl for the week prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- MIRE (Type: ACTIVE_COMPARATOR): Subjects randomized to this arm will receive treatment with monochromatic near infrared photo energy (MIRE).
- Sham (Type: SHAM_COMPARATOR): Subjects randomized to this arm will receive treatment with the sham device, which is non-active but otherwise identical to the study device.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Difficult Intubation in Intensive Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient informed,~* Affiliated or benefit from a disease insurance regimen~* Available for a 28 days follow-up~* Men and women aged aged from at least 18 years~* Indication of intubation in ICU~Exclusion Criteria:~* Protected patient~* Opposition for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intubated patient (Type: EXPERIMENTAL): Adult intubated in Intensive Care Unit (ICU) with The McGrath Mac videolaryngoscope (intervention described)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Multidrug Blister Pack Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Prescription of 4 or more different oral solid drugs~* Capable to understand german (verbally and written)~* Capable to give informed consent~* Insured by a Swiss health insurance~* Manages his/her pharmacotherapy without external support~* Obtains his/her medication from a community pharmacy~* Accepts to use an electronic multidrug blister pack~* Place of domicile in Basel-Stadt or Basel-Land~Exclusion Criteria:~* Pregnancy~* \> 2 drugs that cannot be packed into a multidrug blister pack (e.g. fluids)~* Dementia, or evaluated as cognitively impaired by the responsible nurse~* Transplanted patient~* Anticoagulation with oral vitamin K antagonists~* Has already used a multidrug blister pack of Pharmis or a Medifilm® single dose system~* is visually impaired (blind)~* cannot push drugs through a blister~* refuses to allow contact to his/her regular pharmacy and GP~* is referred to a nursing home or to rehabilitation or another hospital at discharge~* is included in other clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): At hospital discharge, patients of the control group will receive usual care at their community pharmacy.
- Electronic Multidrug Blister Pack (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues